Projects

Study of atorvastatin’s impact in reducing inflammation associated with ageing in HIV-infected patients aged over 60 years receiving treatment based on protease inhibitors compared with treatment based on raltegravir. The two study groups (protease-inhibitor and raltegravir) will receive atorvastatin for 48 weeks. After the switch in treatment, patients will be followed up within 1 month and then every 3 months. In addition to the usual viral load checks, CD4 counts and laboratory analyses, cell, plasma and serum samples will also be collected during the study in order to conduct molecular studies. Densitometry will be performed to see if there are changes to the bone or to body fat distribution.